Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trevogrumab - Regeneron Pharmaceuticals

Next Previous
Drug Profile

Trevogrumab - Regeneron Pharmaceuticals

Alternative Names: GDF8; REGN-1033; SAR-391786

Latest Information Update: 23 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals; Sanofi
  • Class Monoclonal antibodies; Obesity therapies; Osteoporosis therapies
  • Mechanism of Action Myostatin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Obesity; Sarcopenia
  • Phase I Musculoskeletal disorders
  • No development reported Osteoporosis

Most Recent Events

  • 17 Sep 2025 Efficacy and adverse events data from the phase II COURAGE trial in Obesity released by Regeneron Pharmaceuticals
  • 15 Sep 2025 Interim efficacy and adverse event data from the phase II Courage trial in Obesity presented at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD-2025)
  • 02 Jun 2025 Efficacy and adverse events data from phase II COURAGE trials in obesity released by Regeneron Pharmaceuticals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top